Curis, Inc. Announces Collaborator Roche’s Submission of Erivedge(TM) for Registration With Australian Regulatory Authority

LEXINGTON, Mass., May 7, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS - News), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer tre…
Read the full story: BioSpace.com Featured News